Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization

Hsiao Wen Wang, Ping Lun Jiang, Shen Fu Lin, Hung Jun Lin, Keng Liang Ou, Win Ping Deng, Lin Wen Lee, Yi You Huang, Pi Hui Liang, Der Zen Liu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The mucosal immune system produces secretory IgA (sIgA) as the first line of defense against invasion by foreign pathogens. Our aim was to develop a galactose-modified liposome as a targeted carrier which can be specifically recognized by macrophage, one of the most important antigen presenting cells. First, galactose was covalently conjugated with 1,2-didodecanoyl-sn-glycero-3- phosphoethanolamine (DLPE) to give a targeted ligand, a galactosyl lipid. The galactosyl lipid was then incorporated into a liposomal bilayer to form a galactosylated liposome carrier. Further, the ovalbumin (OVA) was encapsulated into the galactosylated liposome carriers and mice were intranasally immunized. Confocal laser scanning microscopy and flow cytometry analysis showed that the targeted galactosylated liposome carrier had a higher uptake rate than unmodified liposomes. The targeted galactosylated liposome induced higher levels of tumor necrosis factor-α and interleukin-6 production than unmodified liposomes (P <0.05). Furthermore, 6-week-old BALB/c female mice immunized with the OVA-encapsulated targeted galactosylated liposome had significantly higher OVA-specific s-IgA levels in the nasal and lung wash fluid (P <0.05). In addition, the targeted galactosylated liposome simultaneously augmented the serum IgG antibody response. In summary, the OVA-encapsulated targeted galactosylated liposome induced significantly higher mucosal IgA and systemic IgG antibody titers and is a potential antigen delivery carrier for further clinical applications.

Original languageEnglish
Pages (from-to)5681-5688
Number of pages8
JournalActa Biomaterialia
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Immunization
Liposomes
Antigen-Presenting Cells
Galactose
Ovalbumin
Antibodies
Immunoglobulin A
Lipids
Laser Scanning Cytometry
Immunoglobulin G
Secretory Immunoglobulin A
Flow cytometry
Macrophages
Immune system
Pathogens
Antigens
Nose
Confocal Microscopy
Antibody Formation
Immune System

Keywords

  • Galactose
  • Mucosal immunity
  • s-IgA
  • Targeted liposomes

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. / Wang, Hsiao Wen; Jiang, Ping Lun; Lin, Shen Fu; Lin, Hung Jun; Ou, Keng Liang; Deng, Win Ping; Lee, Lin Wen; Huang, Yi You; Liang, Pi Hui; Liu, Der Zen.

In: Acta Biomaterialia, Vol. 9, No. 3, 03.2013, p. 5681-5688.

Research output: Contribution to journalArticle

Wang, Hsiao Wen ; Jiang, Ping Lun ; Lin, Shen Fu ; Lin, Hung Jun ; Ou, Keng Liang ; Deng, Win Ping ; Lee, Lin Wen ; Huang, Yi You ; Liang, Pi Hui ; Liu, Der Zen. / Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. In: Acta Biomaterialia. 2013 ; Vol. 9, No. 3. pp. 5681-5688.
@article{ba5e1aa3802c472998ad2f818890bff4,
title = "Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization",
abstract = "The mucosal immune system produces secretory IgA (sIgA) as the first line of defense against invasion by foreign pathogens. Our aim was to develop a galactose-modified liposome as a targeted carrier which can be specifically recognized by macrophage, one of the most important antigen presenting cells. First, galactose was covalently conjugated with 1,2-didodecanoyl-sn-glycero-3- phosphoethanolamine (DLPE) to give a targeted ligand, a galactosyl lipid. The galactosyl lipid was then incorporated into a liposomal bilayer to form a galactosylated liposome carrier. Further, the ovalbumin (OVA) was encapsulated into the galactosylated liposome carriers and mice were intranasally immunized. Confocal laser scanning microscopy and flow cytometry analysis showed that the targeted galactosylated liposome carrier had a higher uptake rate than unmodified liposomes. The targeted galactosylated liposome induced higher levels of tumor necrosis factor-α and interleukin-6 production than unmodified liposomes (P <0.05). Furthermore, 6-week-old BALB/c female mice immunized with the OVA-encapsulated targeted galactosylated liposome had significantly higher OVA-specific s-IgA levels in the nasal and lung wash fluid (P <0.05). In addition, the targeted galactosylated liposome simultaneously augmented the serum IgG antibody response. In summary, the OVA-encapsulated targeted galactosylated liposome induced significantly higher mucosal IgA and systemic IgG antibody titers and is a potential antigen delivery carrier for further clinical applications.",
keywords = "Galactose, Mucosal immunity, s-IgA, Targeted liposomes",
author = "Wang, {Hsiao Wen} and Jiang, {Ping Lun} and Lin, {Shen Fu} and Lin, {Hung Jun} and Ou, {Keng Liang} and Deng, {Win Ping} and Lee, {Lin Wen} and Huang, {Yi You} and Liang, {Pi Hui} and Liu, {Der Zen}",
year = "2013",
month = "3",
doi = "10.1016/j.actbio.2012.11.007",
language = "English",
volume = "9",
pages = "5681--5688",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization

AU - Wang, Hsiao Wen

AU - Jiang, Ping Lun

AU - Lin, Shen Fu

AU - Lin, Hung Jun

AU - Ou, Keng Liang

AU - Deng, Win Ping

AU - Lee, Lin Wen

AU - Huang, Yi You

AU - Liang, Pi Hui

AU - Liu, Der Zen

PY - 2013/3

Y1 - 2013/3

N2 - The mucosal immune system produces secretory IgA (sIgA) as the first line of defense against invasion by foreign pathogens. Our aim was to develop a galactose-modified liposome as a targeted carrier which can be specifically recognized by macrophage, one of the most important antigen presenting cells. First, galactose was covalently conjugated with 1,2-didodecanoyl-sn-glycero-3- phosphoethanolamine (DLPE) to give a targeted ligand, a galactosyl lipid. The galactosyl lipid was then incorporated into a liposomal bilayer to form a galactosylated liposome carrier. Further, the ovalbumin (OVA) was encapsulated into the galactosylated liposome carriers and mice were intranasally immunized. Confocal laser scanning microscopy and flow cytometry analysis showed that the targeted galactosylated liposome carrier had a higher uptake rate than unmodified liposomes. The targeted galactosylated liposome induced higher levels of tumor necrosis factor-α and interleukin-6 production than unmodified liposomes (P <0.05). Furthermore, 6-week-old BALB/c female mice immunized with the OVA-encapsulated targeted galactosylated liposome had significantly higher OVA-specific s-IgA levels in the nasal and lung wash fluid (P <0.05). In addition, the targeted galactosylated liposome simultaneously augmented the serum IgG antibody response. In summary, the OVA-encapsulated targeted galactosylated liposome induced significantly higher mucosal IgA and systemic IgG antibody titers and is a potential antigen delivery carrier for further clinical applications.

AB - The mucosal immune system produces secretory IgA (sIgA) as the first line of defense against invasion by foreign pathogens. Our aim was to develop a galactose-modified liposome as a targeted carrier which can be specifically recognized by macrophage, one of the most important antigen presenting cells. First, galactose was covalently conjugated with 1,2-didodecanoyl-sn-glycero-3- phosphoethanolamine (DLPE) to give a targeted ligand, a galactosyl lipid. The galactosyl lipid was then incorporated into a liposomal bilayer to form a galactosylated liposome carrier. Further, the ovalbumin (OVA) was encapsulated into the galactosylated liposome carriers and mice were intranasally immunized. Confocal laser scanning microscopy and flow cytometry analysis showed that the targeted galactosylated liposome carrier had a higher uptake rate than unmodified liposomes. The targeted galactosylated liposome induced higher levels of tumor necrosis factor-α and interleukin-6 production than unmodified liposomes (P <0.05). Furthermore, 6-week-old BALB/c female mice immunized with the OVA-encapsulated targeted galactosylated liposome had significantly higher OVA-specific s-IgA levels in the nasal and lung wash fluid (P <0.05). In addition, the targeted galactosylated liposome simultaneously augmented the serum IgG antibody response. In summary, the OVA-encapsulated targeted galactosylated liposome induced significantly higher mucosal IgA and systemic IgG antibody titers and is a potential antigen delivery carrier for further clinical applications.

KW - Galactose

KW - Mucosal immunity

KW - s-IgA

KW - Targeted liposomes

UR - http://www.scopus.com/inward/record.url?scp=84873160323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873160323&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2012.11.007

DO - 10.1016/j.actbio.2012.11.007

M3 - Article

C2 - 23159567

AN - SCOPUS:84873160323

VL - 9

SP - 5681

EP - 5688

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 3

ER -